Noxopharm’s collaboration finds drug to help stroke victims

Company News

by Jessica Amir

Noxopharm (ASX:NOX) and its UNSW Sydney collaboration have revealed a drug candidate known NYX-104 has the ability to help stroke, concussion and head trauma patients and people who suffer from severe epileptic seizures.

The collaborative parties say the drug has the ability to significantly reduce the area of brain death in a mouse model of human stroke.

The drug can’t treat the original injury but stops the cascade of nerve cells dying, which occurs in the brain and spinal cord after an initial injury.

The company says there is a significant opportunity to reduce rehab time following a stroke, head or spinal injury.

Shares in Noxopharm (ASX:NOX) closed 8 per cent lower to 58 cents.

Jessica Amir

Finance News Network
Jessica is the head of news and a senior finance journalist and presents bulletins including the Market Outlook, Market at Midday and Market Wrap. She also interviews ASX CEOs and leading fund managers. She joined FNN in January 2017 with over six years of broadcast journalism experience including with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for Prime 7 and WIN News. Jessica has worked in financial planning for over six years with leading wealth managers and in real estate.